Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Author: Don Stader, MD
Educational Pearls:
- Etripamil is an intranasal calcium channel blocker in development for use in SVT
- A recent study showed that etripamil has an SVT conversion rate of around 80%
- Etripamil does not have the same feeling of "impending doom" that can occur with adenosine
Editor's note: Etripamil is still in development and these results are from a phase II clinical trial.
References:
Stambler BS, Dorian P, Sager PT, Wight D, Douville P, Potvin D, Shamszad P, Haberman RJ, Kuk RS, Lakkireddy DR, Teixeira JM, Bilchick KC, Damle RS, Bernstein RC, Lam WW, O'Neill G, Noseworthy PA, Venkatachalam KL, Coutu B, Mondésert B, Plat F. Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm. J Am Coll Cardiol. 2018 Jul 31;72(5):489-497. doi: 10.1016/j.jacc.2018.04.082. PubMed PMID: 30049309.
Summarized by Travis Barlock, MS4 | Edited by Erik Verzemnieks, MD